Harrow Health Inc
NASDAQ:HROW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Harrow Health Inc
NASDAQ:HROW
|
US |
|
Taiyuan Heavy Industry Co Ltd
SSE:600169
|
CN |
Relative Value
The Relative Value of one
HROW
stock under the Base Case scenario is
50.83
USD.
Compared to the current market price of 33.28 USD,
Harrow Health Inc
is
Undervalued by 35%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
HROW Competitors Multiples
Harrow Health Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Harrow Health Inc
NASDAQ:HROW
|
1.2B USD | 4.6 | -241.1 | 28.5 | 46.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD | 13.1 | 41.5 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.6 | 11.1 | 12.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.5B GBP | 4.9 | 28.3 | 15.7 | 22.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 5 | 20.2 | 12.5 | 16.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.1 | 7.5 | 8.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.5 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD | 2.4 | 16.4 | 7 | 8.6 |